In the Claims

Amend the claims as follows:

Please cancel claims 1-4 and 11-12 as drawn to non-elected inventions, as well as claim 6. Please amend the claims as follows:

1. – 4. (Cancelled)

5. (Currently Amended) A method of treating ~~proliferative cell diseases~~ cancer in a human patient in need of such treatment comprising administering ~~ration~~ to such pateint ~~of~~ a cytocidally effective dose of ~~the composition of claim 1 individual in need of said treatment~~ a composition comprising an antibody directed toward a cell surface associated antigen conjugated or fused to biological response modifier, wherein it has been determined that cells of the patient's cancer express an antigen recognized and bound by the antibody.

6. (Cancelled)

7. (Currently Amended) The method of claim 5~~6~~, wherein said cancer is selected from the group consisting of breast cancer, cervical carcinoma and melanoma.

8. (Currently Amended) The method of claim 7, wherein the patient has been diagnosed as having a breast tumor bearing a ~~A method of treating human breast carcinoma comprising administration of a cytotoxic or cytostatic dose of TNF conjugated monoclonal antibody 15A8 to an individual diagnosed as having a tumor bearing~~ 15A8 tumor associated antigen and the

antibody is a monoclonal antibody that recognizes and binds to the 15A8 tumor associated antigen.

9. (Currently amended) The method of claim 7, wherein the patient has been diagnosed with a cervical carcinoma bearing a~~A method of treating cervical carcinoma comprising administration of a pharmacologically effective dose of TNF conjugated monoclonal antibody directed against~~ 15A8 tumor associated antigen ~~to an individual in need of said treatment~~ and the antibody is a monoclonal antibody that recognizes and binds to the 158A tumor associated antigen.

10. (Currently amended) The method of claim 7, wherein the patient has been diagnosed with cancer and cells of the cancer express an antigen recognized by monoclonal antigody ZME-018, and further wherein the antibody is a monoclonal antibody that recognizes and binds the antigen ~~treating melanoma comprising administration of a pharmacologically effective dose of a TNF conjugated monoclonal antibody ZME-018 to an individual in need of said treatment~~.

11. – 12. (Cancelled)

13. (New) The method of claim 5, wherein the biological response modifier is a cytokine.

14. (New) The method of claim 13, wherein the cytokine is TNF.

15. (New) The method of claim 14, wherein the TNF is TNF-beta.

16. (New) The method of claim 14, wherein the TNF is TNF-alpha.

17. (New) The method of claim 13, wherein the cytokine is an interleukin.

18. (New) The method of claim 17, wherein the interleukin is interleukin-1 or interleukin-6.

19. (New) The method of claim 13 wherein the cytokine is an interferon.

20. (New) The method of claim 5, wherein the antibody recognizes and binds to the 15A8 tumor associated antigen.

21. (New) The method of claim 5, wherein the antibody recognizes and binds to the ZME-018 antigen.

22. (New) The method of claim 5, wherein the antibody recognizes and binds to the antigen recognized by the 465.12 antibody.

23. (New) The method of claim 5, wherein the antibody is fused to the biological response modifier.

24. (New) The method of claim 5, wherein the antibody is conjugated to the biological response modifier.

25. (New) The method of claim 5, wherein the antibody recognizes and binds to the ZME-018 antigen.

26. (New) The method of claim 5, further defined as comprising the steps of:

(a) identifying a patient having a tumor, which tumor comprises cells for targeting and wherein those cells comprise a cell surface antigenic marker at concentrations in excess of that found at other non-target sites;

(b) obtaining a composition comprising an antibody directed toward a cell surface associated antigen conjugated or fused to biological response modifier, wherein it has been determined that cells of the patient's cancer express an antigen recognized and bound by the antibody; and

(c) administering an amount of the composition to the patient effective to treat the cancer.

27. (New) The method of claim 26, wherein the patient is diagnosed as having a tumor with a specific antigenic determinant that will allow targeting and concentration of the biological response modifier at the site where it is needed to kill tumor cells.